reported a $320 million investment to establish operations in Singapore for small molecule and biologics active drug-substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline.
The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include R&D functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie’s existing presence in Singapore includes 120 employees, supporting commercial operations, global R&D, and general operations.
The investment is expected to result in more than 250 new employees. The new facility is expected to be fully operational by 2019.